Ivermectin is not going away!
The attached research article by regular contributor David Cuthill revisits Ivermectin from a scholarly evaluation viewpoint.
Ivermectin, a well-known anti-parasitic drug, has garnered research interest for potential anticancer properties. While lab-based studies are promising, clinical validation is limited. This report provides a rigorous analysis of its mechanisms, supporting research, and current standing.
